CINECA IRIS Institutional Research Information System

AMBROGIO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.942
EU - Europa 1.941
AS - Asia 1.004
OC - Oceania 15
SA - Sud America 15
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.882
IT - Italia 624
CN - Cina 440
SG - Singapore 296
DK - Danimarca 222
SE - Svezia 216
IE - Irlanda 208
DE - Germania 138
UA - Ucraina 97
FR - Francia 94
FI - Finlandia 81
AT - Austria 75
CA - Canada 48
JP - Giappone 43
GB - Regno Unito 41
IN - India 41
KR - Corea 40
VN - Vietnam 40
HK - Hong Kong 38
ES - Italia 32
PL - Polonia 30
ID - Indonesia 23
BE - Belgio 17
PT - Portogallo 15
AU - Australia 13
GR - Grecia 10
MX - Messico 10
TW - Taiwan 10
BR - Brasile 9
CH - Svizzera 8
NL - Olanda 8
RU - Federazione Russa 8
TR - Turchia 7
IL - Israele 5
MY - Malesia 5
NO - Norvegia 4
SN - Senegal 4
AR - Argentina 3
MK - Macedonia 3
PE - Perù 3
PH - Filippine 3
AM - Armenia 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
EG - Egitto 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
RO - Romania 2
TH - Thailandia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CI - Costa d'Avorio 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EU - Europa 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
LT - Lituania 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
PK - Pakistan 1
QA - Qatar 1
SA - Arabia Saudita 1
TM - Turkmenistan 1
TN - Tunisia 1
Totale 5.928
Salva come PNG Salva come JPEG
Città #
Ann Arbor 329
Chandler 324
Santa Clara 296
Singapore 245
Dublin 208
Beijing 202
Ashburn 165
Turin 160
Houston 128
Fairfield 120
Torino 113
Jacksonville 82
Wilmington 77
Nyköping 76
Vienna 71
Woodbridge 66
Cambridge 65
Columbus 62
Princeton 53
Dearborn 45
Medford 43
Villeurbanne 43
Seattle 41
Chieri 38
Shanghai 34
Boston 32
Milan 30
Dong Ket 29
Fremont 29
Warsaw 26
Pisa 24
Jakarta 22
Redwood City 22
Hangzhou 21
Tokyo 20
Guangzhou 19
Helsinki 18
Boardman 17
Brussels 15
Nanjing 14
Rome 14
Grafing 13
Munich 13
San Diego 13
Chengdu 12
Madrid 12
Washington 12
Falls Church 11
Hong Kong 11
Los Angeles 11
New York 11
Occimiano 10
Dallas 9
Hefei 9
Ottawa 9
Trento 9
Vancouver 9
Aprilia 8
Pune 8
Central District 7
Norwalk 7
Porcia 7
San Mateo 7
Chennai 6
Chicago 6
Genoa 6
Montréal 6
Nuremberg 6
Paris 6
Silver Spring 6
Toronto 6
Verona 6
Barcelona 5
Bari 5
El Paso 5
Kunming 5
Lappeenranta 5
Lissone 5
Nürnberg 5
San Jose 5
Saskatoon 5
Seoul 5
Shenzhen 5
Trieste 5
Bologna 4
Buffalo 4
Catania 4
Central 4
Changsha 4
Düsseldorf 4
Edison 4
Florence 4
Guiyang 4
Hyderabad 4
Jinan 4
Khabarovsk 4
Liverpool 4
Manchester 4
New Haven 4
Palaiseau 4
Totale 3.834
Salva come PNG Salva come JPEG
Nome #
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells 386
KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer 278
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 253
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 252
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma 247
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 234
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 229
Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin 221
Redundant and non-redundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice 198
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. 138
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 115
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. 112
The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase 101
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer 101
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination 95
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis 94
Expression of IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma signaling and apoptosis in human T lymphocytes 93
PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. 93
Human Wrnip1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner 93
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas 90
Molecola perturbation of IFNγR2 internalization reinstates T cell sensitività to the IFNγ/STAT1 signaling pathway in vitro and in vivo. 5th 88
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 88
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC) 87
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 86
Discoveries in the redox regulation of KRAS 84
A Braf kinase-inactive mutant induces lung adenocarcinoma 83
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 82
Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis 80
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA 79
Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice 79
ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer 78
Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. 76
Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage 74
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 72
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer 72
A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance 71
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma 68
The anaplastic lymphoma kinase in the pathogenesis of cancer 67
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma 64
TTC3 protein inhibits neuronal differentiation through RhoA and CITRON dependent mechanism 62
Lentiviral-based approach for the validation of cancer therapeutic targets in vivo 61
Cancer Hallmarks: Piecing the Puzzle Together 59
YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors 54
Simple and Rapid InVivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology 54
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts 53
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 49
MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. 48
Assessing therapeutic efficacy of MEK inhibition in a KrasG12C-driven mouse model of lung cancer 48
TTC3 protein inhibits neuronal differentiation through a RhoA dependent mechanism 47
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 46
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer 46
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 46
The Tyrosine Phosphatase SHP2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. 44
Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer 42
A structural model of a Ras–Raf signalosome 42
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS 41
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node 39
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 35
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer 35
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy 33
The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 29
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases 29
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma 28
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer 24
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade 21
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models 21
Experimental variables determine the outcome of RAS-RAS interactions 19
A LIBRETTO to orchestrate targeted therapy 19
Active thymus in adult with lung cancer: preliminary results from the Adult Thymic Project 12
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma 11
Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers 10
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors 7
scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers 2
Totale 6.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.200
article - articoli 0
book - libri 0
conference - conferenze 850
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.050
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020469 0 0 0 0 0 0 84 63 101 78 76 67
2020/2021689 68 40 70 23 81 30 41 31 70 73 66 96
2021/2022922 80 56 49 67 47 46 58 63 55 75 202 124
2022/20231.084 122 106 25 103 82 278 95 59 95 35 42 42
2023/2024660 59 77 40 59 45 112 29 47 4 46 75 67
2024/20251.046 33 97 68 201 430 198 19 0 0 0 0 0
Totale 6.117